Scailyte develops biomarker signatures and assay prototypes for complex diseases. We license our discoveries or engage in co-development projects with diagnostic companies willing to build products and services.
We identify and validate biomarkers and prototype assays for:
- Screening and diagnosis
- Prediction of therapy response
ScaiVision accurately diagnoses Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is a rare skin cancer that is often misdiagnosed with atopic dermatitis (AD), a highly prevalent skin condition with similar clinical presentation. Currently used markers and assays have low sensitivity and are inconclusive to diagnose CTCL in early stages, leading to disease progression and up to 5-year delay in diagnosis. Advanced-stage diagnosis requires highly aggressive and costly chemotherapy treatment causing severe side effects.
To address the differential CTCL diagnosis need, we identified CTCL-specific biomarkers using our proprietary single-cell data analysis platform ScaiVision. We have developed an IVD assay prototype using these biomarkers for simple, minimally invasive and cost-effective testing of suspected CTCL patients. The assay enables timely intervention, improves patient Quality of Life (QoL), dramatically reduces treatment costs associated with late-stage/misdiagnosis/comorbidities and, ultimately, saves lives.
Scailyte’s CTCL IVD assay will be the first clinically validated blood-based diagnostic test for CTCL with superior accuracy as compared to the current standard of care diagnostics. The assay will be used to screen recurrent AD patients suspected of CTCL. This approach offers rapid triage of recurrent AD patients at dermatology clinics. The assay will shorten diagnosis up to five years, reducing hospital costs associated with repeated visits and less accurate tests by allowing early treatment and improved patient outcome.
Are you interested in in-licensing a biomarker signature or a diagnostic assay prototype? Would you like to develop an assay for your indication of interest? Let’s discuss our ongoing projects and your specific needs.